Deslorelin vs PEG-MGF
A neutral, side-by-side comparison of two performance & growth hormone peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
Deslorelin
Potent GnRH super agonist approximately 100× more potent than native GnRH. Used in veterinary medicine for estrus suppression and in human medicine for precocious puberty treatment. In research protocols, used for pituitary desensitization to reset the HPG axis or induce controlled medical suppression of sex hormone production.
Full profilePEG-MGF
PEG-MGF is Mechano Growth Factor (MGF) conjugated to a polyethylene glycol (PEG) polymer chain. The PEGylation dramatically extends the half-life from ~5 minutes (native MGF) to approximately 24–72 hours, allowing less frequent dosing and systemic distribution rather than purely local action. This trade-off — longer duration vs localized intensity — makes PEG-MGF a different tool than native MGF, better suited for systemic muscle recovery support and convenience-focused protocols.
Full profile| Deslorelin | PEG-MGF | |
|---|---|---|
| Category | Performance & Growth Hormone | Performance & Growth Hormone |
| Also known as | SuvaPryn, Ovuplant, D-His6-Pro9-Et-GnRH | PEGylated Mechano Growth Factor, Polyethylene Glycol-MGF, Long-acting MGF |
| Evidence | Research-stage | Preclinical only |
| Dosing range | 50mcg–200mcg mcg, Daily SC for continuous suppression; single or short course for pituitary reset | 100mcg–400mcg mcg, 2x weekly (Monday/Thursday or similar split) |
| Administration | Subcutaneous implant (veterinary), Subcutaneous injection | Subcutaneous injection (preferred for systemic distribution), Intramuscular injection |
| Key side effects | Hot flashes, Bone density loss (prolonged suppression), Suppression of testosterone or estrogen, Mood changes, irritability | Hypoglycemia (less pronounced than IGF-1 DES, more than native MGF due to systemic distribution), Generalized fatigue on injection days, PEG accumulation concern with very high doses over long periods (theoretical — not established at research doses), Localized injection site swelling |
| Cited sources | 2 references | 2 references |
Key differences
- Evidence level differs: Deslorelin is research-stage, while PEG-MGF is preclinical only.
- Administration: Deslorelin — Subcutaneous implant (veterinary), Subcutaneous injection; PEG-MGF — Subcutaneous injection (preferred for systemic distribution), Intramuscular injection.
- Frequency: Deslorelin is typically Daily SC for continuous suppression; single or short course for pituitary reset; PEG-MGF is 2x weekly (Monday/Thursday or similar split).
How each works
Deslorelin
Deslorelin produces a robust initial LH/FSH surge (flare effect) followed by profound, sustained pituitary desensitization with continued exposure. This biphasic response is consistent across all high-affinity GnRH super agonists. The flare phase is exploited for reproductive timing in veterinary medicine; the desensitization phase creates the clinical suppression used in precocious puberty and research HPG axis reset protocols.
PEG-MGF
PEGylation is a validated pharmaceutical strategy for extending peptide half-life (used in Pegasys/interferon, Somavert/pegvisomant, and others). The PEG chain shields the MGF peptide from proteolytic degradation and slows renal clearance. Research in rodent models confirms PEG-MGF preserves the biological activity of native MGF (satellite cell activation, muscle repair) with extended duration. Unlike native MGF which requires precise post-workout injection timing, PEG-MGF can be injected on a scheduled basis and still achieves systemic muscle-wide satellite cell effects.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.